TAB2 and prostate carcinoma: The Tab2 protein (also known as TGF-β activated kinase 1/MAP3K7 binding protein 2) has been implicated in the mechanisms of resistance to steroid antagonists in breast and prostate cancer, contributing an additional piece of the jigsaw to the long-standing concept of cross-talk between inflammation and hormonal response, as well as between inflammation and cancer.